bioihbjkbjnl/mcl2 huggingface dataset:
Dexmedetomidine Versus Fentanyl Added to Levobupivacaine for Transversus Abdominis Plane (TAP) Block
Condition: Transversus Abdominis Block
Study type: Interventional
Phase: Phase 1/Phase 2

Summary: 
      The perioperative management of pain following lower abdominal surgery can pose a challenge
      to anesthesia providers. Conventional practice has involved the use of opioids as well as
      neuraxial analgesic techniques. Unfortunately, these therapies are not without potential
      risks and side effects. These include nausea, vomiting, pruritus, urinary retention,
      constipation, respiratory depression, and sedation.
    

Detailed description: 
      One method used in this multimodal approach is the transversus abdominis plane block. This
      block, as first described by Rafi. in 2001, provides analgesia to the anterolateral abdominal
      wall. In 2007, McDonnell et al. further studied this technique in patients undergoing
      large-bowel resection. He discovered a reduction in postoperative pain and morphine
      consumption in the first 24 hours postoperatively, resulting in fewer opioid mediated side
      effects. In this same year, Hebbard et al. described the use of ultrasound guidance to
      provide real-time imaging of the muscle layers and needle placement to improve transversus
      abdominis plane block accuracy. In 2008, Hebbard. described the subcostal approach of
      transversus abdominis plane block, to target the nerves of the upper abdomen. Transversus
      abdominis plane blocks continue to be studied and developed as an effective method for
      providing analgesia for numerous types of transverses abdominis plane block duration is
      limited to effect of administered local anesthetics.The use of an infusion catheter to
      administer local anesthetics is an option to prolong the block's duration. Recently, adjuvant
      medications were added to local anesthetics to prolong the effect of transverses abdominis
      plane block .
    

Intervention name(s): Levobupivacaine; Dexmedetomidine Injection [Precedex]; fentanyl
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Patients will receive Levobupivacaine 5%; Patients will receive Levobupivacaine 5% + 1 µg/kg dexmedetomedine; Patients will receive Levobupivacaine 5% + 1 µg/kg fentanyl
Other intervention name(s): Levobupivacaine hydrate
Intervention MeSH terms: Fentanyl; Dexmedetomidine; Levobupivacaine
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Treatment
Keywords: transversus abdominis plane block; Dexmedetomidine; Fentanyl
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
Condition: Leukemia; Lymphoma; Myelodysplastic Syndrome
MeSH terms: Myelodysplastic Syndromes
Study type: Interventional
Phase: Phase 2

Summary: 
      A common problem after stem cell transplant is graft-versus-host-disease (GVHD). GVHD is a
      complication of transplantation where the donor graft attacks and damages some of your
      tissues. After stem cell transplant, all patients receive prophylactic medications against
      GVHD.

      In this research study, we are studying the safety and effectiveness of a bortezomib based
      GVHD prophylaxic drug combination in participants after myeloablative allogeneic stem call
      transplantation from a matched unrelated donor, mismatched related or unrelated donor.
    

Detailed description: 
      Before your transplant you will receive conditioning therapy with fludarabine and busulfan
      given 7, 6, 5, and 4 days before your transplant. On day 0, you will receive selected blood
      cells taken from your sibling or unrelated donor.

      You will receive 3 drugs for your GVHD prophylaxis:

      Tacrolimus will be started 3 days before your transplant. It will be given intravenously and
      later by mouth. You will continue to take tacrolimus for 3 to 6 months after transplant.

      Methotrexate will be given intravenously 1, 3, 6 and 11 days after your transplant.

      Bortezomib will be given intravenously 1, 4, and 7 days after your transplant. On days 1, 4,
      7, 30 and 3, 6 and 12 months after your transplant you will have a physical exam, blood work,
      and be asked to complete a questionnaire.
    

Intervention name(s): Bortezomib; Tacrolimus; Methotrexate
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Bortezomib 1.3 mg/m^2 IV; Tacrolimus 0.05 mg/kg PO bid; Methotrexate 15 mg/m^2 IV
Other intervention name(s): Velcade
Intervention MeSH terms: Methotrexate; Bortezomib; Tacrolimus
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Stem Cell Transplant; Allogeneic Transplant; Donors
The Effect of a Breakfast Meal Containing Oat β-glucan on Food Intake at a Subsequent Meal in Normal-weight and Overweight Subjects
Condition: Satiety
MeSH terms: Overweight
Study type: Interventional

Summary: 
      The objectives of this study are to determine, in normal-weight and overweight subjects the
      effect of: Primary: oatmeal containing 4 g oat β-glucan on food intake at a subsequent meal
      compared to Cream of Rice cereal. Secondary: (i) oatmeal containing 2 g oat β-glucan on food
      intake at a subsequent meal compared to Cream of Rice cereal; and (ii) oatmeal containing 2g,
      4g and 4g low MW oat beta-glucan on subjective appetite ratings, gastric emptying,
      postprandial responses of glucose, insulin, ghrelin and PYY levels compared to those elicited
      by Cream of Rice cereal. In addition, the relationship between amount, MW and viscosity of
      OBG and the primary and secondary objectives will be determined.
    


Intervention name(s): Oatmeal + OatWell28CF Int 1; Oatmeal + OatWell28CF Int 2; Oatmeal + OatWell28CF Int 3; Cream of Rice
Intervention type(s): Other; Other; Other; Other
Intervention description(s): Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.; Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.; Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.; Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Basic Science
Effect of Ventilation Mode on Lung Deposition of a Radiolabeled Aerosol During Mechanical Ventilation: Barometric Versus Volumetric
Condition: Post-operative Neurosurgery
Study type: Interventional

Summary: 
      Controlling the respiratory pattern of mechanically ventilated patients in volume control
      mode is recommended during nebulization. No studies looked into conditions of nebulization
      during assisted mechanical ventilation to define the optimal nebulization technique and its
      effect on pulmonary deposition.

      The aim of this study is to analyse the effect of ventilation mode (barometric versus
      volumetric) on deposition by planar scintigraphy during mechanical ventilation.
    


Intervention name(s): technetium-99m - Diethylenetriaminepentaacetic acid; Vibrating-mesh nebulizer; Gamma scintigraphy; Preoperative spirometry
Intervention type(s): Drug; Device; Other; Other
Intervention MeSH terms: Edetic Acid; Pentetic Acid
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: Aerosol; Lung deposition; Mechanical ventilation
Seasonal Malaria Chemoprevention Versus Home Management of Malaria in Children Under 5 Years in Ghana
Condition: Malaria; Anaemia
MeSH terms: Malaria; Anemia
Study type: Interventional
Phase: Phase 4

Summary: 
      In areas of Africa where malaria is only a problem during a short rainy season, monthly
      courses of antimalarial drugs can provide very effective prevention of malaria in children.
      This approach, called intermittent preventive treatment in children (IPTc) but now known as
      Seasonal Malaria Chemoprevention (SMC), may also be useful in large areas of Africa where
      malaria is transmitted for longer each year. It is uncertain if IPTc would be effective,
      acceptable to communities or sustainable when delivered over a longer period, but this is an
      important public health question of key interest to policy makers, because in areas with a
      longer transmission season, the burden of malaria is typically higher than in highly seasonal
      areas.

      Another form of prevention that would be operationally easier for African countries to put
      into practice would be to treat malaria patients with long-lasting antimalarials, which
      protect children against further malaria episodes for several weeks. Because malaria
      disproportionately affects certain high risk children more than others, causing repeated
      attacks of fever and leading to severe anaemia, long-acting drugs may be a simple and
      effective way to target limited resources at the individuals who most need protection. This
      may be particularly beneficial where malaria is a seasonal problem, because repeated malaria
      attacks will not only be borne by a few unfortunate children, but will also occur close
      together in time.

      The investigators propose a clinical trial to evaluate these two forms of chemoprevention in
      Kumasi, Ghana, an area with an extended malaria transmission season. Children under 5 years
      of age currently have access to diagnosis and treatment of malaria via by community based
      health workers. Children enrolled in the study will receive either the standard
      community-based diagnosis and treatment, treatment with a longer-acting artemisinin
      combination therapy (ACT), or standard care plus five monthly courses of seasonal malaria
      chemoprevention (SMC) during the peak in transmission.
    


Intervention name(s): Artemether-lumefantrine combination; Dihydroartemisinin Piperaquine combination; Amodiaquine plus sulphadoxine-pyrimethamine combination
Intervention type(s): Drug; Drug; Drug
Other intervention name(s): Duo-cotecxin
Intervention MeSH terms: Lumefantrine; Pyrimethamine; Artemether; Piperaquine; Sulfadoxine; Artemether, Lumefantrine Drug Combination; Fanasil, pyrimethamine drug combination; Amodiaquine; Artenimol
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Prevention
Keywords: Home management of malaria; Seasonal malaria chemoprevention
A Study To Look At The Safety Of SB-681323 In Healthy Adult Subjects After Intravenous Administration Of A Single Dose
Condition: Arthritis, Rheumatoid; Inflammation
MeSH terms: Arthritis; Arthritis, Rheumatoid; Inflammation
Study type: Interventional
Phase: Phase 1

Summary: 
      SB-681323 inhibits the action of an enzyme which is known to contribute to the inflammation
      seen in such conditions as Chronic Obstructive Pulmonary Disease and Rheumatoid Arthritis.
      This study will explore the safety of this drug and its blood levels when given in
      intravenous form to healthy human volunteers.
    


Intervention name(s): SB-681323
Intervention type(s): Drug
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Diagnostic
Keywords: inflammation,; intravenous,; Chronic Obstructive Pulmonary Disease,; P38 inhibitor; SB-681323,; rheumatoid arthritis,
Tuberculosis in HIV Infected Patients in Uganda
Condition: Tuberculosis; HIV Infections
MeSH terms: Infections; HIV Infections; Acquired Immunodeficiency Syndrome; Tuberculosis
Study type: Interventional
Phase: Phase 2

Summary: 
      This was a clinical trial in HIV infected patients with tuberculosis. The study assessed
      whether the addition of prednisolone, a type of steroid medication, to the standard treatment
      for tuberculosis improved immune and viral outcomes in the patients. The study demonstrated
      that prednisolone increased the CD4 cell count as was hoped, but the beneficial effect was
      short-lived and was gone within 4 months of stopping therapy. Therefore, the use of
      prednisolone for tuberculosis in HIV infected patients is not recommended at this time.
    

Detailed description: 
      Recent observations from retrospective cohort studies indicate that HIV-associated
      tuberculosis (TB) is associated with reduced survival and increased rate of opportunistic
      infections compared to CD4-matched controls. Mounting evidence from immunologic and virologic
      studies supports the concept of co-pathogenesis, in which cytokines such as tumor necrosis
      factor alpha (TNF alpha) are over-expressed during the course of TB and stimulate viral
      replication in latently infected cells, possibly leading to greater viral load.

      Glucocorticoids are potent inhibitors of cytokines, including TNF, and clinicians have
      extensive experiences with their use in HIV infection. Although corticosteroid use in HIV
      infection has a record of safety, the safety and bioavailability of corticosteroids in HIV/TB
      coinfection has not been established.

      This study evaluated the change in viral load and CD4 count in HIV infected patients with TB
      who were treated with oral prednisolone. The study found that the viral load increased
      slightly when prednisolone was administered and that patients receiving prednisolone cleared
      their tuberculosis more rapidly. Although there was some benefit to using prednisolone in
      these patients, the benefit was short-lived and was gone within 4 months of stopping therapy.
    

Intervention name(s): prednisolone
Intervention type(s): Drug
Intervention MeSH terms: Prednisolone
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double
Primary purpose: Treatment
Keywords: Tuberculosis; HIV infection; Prednisolone; Safety; Immune activation
Effects Of Power Ball Exercises In Addition To Routine Physical Therapy In Patients With Carpal Tunnel Syndrome
Condition: Carpal Tunnel Syndrome
MeSH terms: Carpal Tunnel Syndrome; Syndrome
Study type: Interventional

Summary: 
      The purpose for doing this study is to determine that whether use of Power Ball in form of
      resistance training will be effective in increasing grip strength in carpel tunnel syndrome
      patient and possible benefits of the regime as effective means of rehabilitation for wrist
      and hand injuries. Moreover for increasing grip strength it can be used as an adjunct for
      physical therapy treatment.
    


Intervention name(s): Routine Physical Therapy; Powerball Exercises
Intervention type(s): Other; Other
Intervention description(s): Participants will receive routine physical therapy which includes ultrasound, nerve gliding, tendon mobilization, stretching, mobility and strengthening exercises for the wrist. Each session will last for 30 minutes with 12 sessions on alternate days (3 sessions / week).; Participants will be using the Powerball™ for 5 minutes per hand, 3 times a week along with routine physical therapy exercises.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
Keywords: Physical therapy; Median Neuropathy; Power Ball Exercise; Carpal Tunnel Syndrome
An Open Trial to Assess the Tolerability of AVANZ Olive Immunotherapy
Condition: Allergic Rhinitis Due to Olea Europaea Pollen
MeSH terms: Rhinitis; Rhinitis, Allergic
Study type: Interventional
Phase: Phase 2/Phase 3

Summary: 
      This trial is an open, national, multi-centre trial. The trial will be initiated after olive
      pollen season 2012 and subjects will receive treatment for 6 weeks.

      The aim of study is to assess the tolerability of the up-dosing phase of AVANZ Olive. The
      frequency of patients with adverse reactions will be the primary endpoint.

      Frequency of patients with systemic reactions according to EAACI classification, increase in
      IgG4 and in IgE and reduction in immediate skin reactivity.
    


Intervention name(s): AVANZ olea
Intervention type(s): Biological
Intervention description(s): Immunotherapy Olea europaea
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Olea sensitization
Laparoscopic Versus Open Left Hemihepatectomy for Liver Benign Lesions
Condition: Benign Lesions in Left Liver
Study type: Interventional

Summary: 
      The purpose of this study is to investigate the influence of the laparoscopic and open left
      hemihepatectomy on acute surgical trauma and stress response.
    


Intervention name(s): Laparoscopic left hemihepatectomy; Open left hemihepatectomy
Intervention type(s): Procedure; Procedure
Intervention description(s): participants will be performed with laparoscopic left hepatectomy using laparoscopic instruments; participants will be performed with traditional open left hepatectomy using laparotomic instruments
Other intervention name(s): Laparoscopic left hepatectomy; Open left hepatectomy
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions
Condition: Acid Reflux; Gastro Oesophageal Reflux Disease
MeSH terms: Gastroesophageal Reflux
Study type: Interventional
Phase: Phase 1

Summary: 
      The purpose of this study is to assess the effectiveness of Zegerid 20mg capsules and powder
      and Losec 20mg capsules in healthy volunteers under fasting conditions.
    


Intervention name(s): Zegerid; Losec
Intervention type(s): Drug; Drug
Intervention MeSH terms: Omeprazole, sodium bicarbonate drug combination
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Treatment
TMS for Post Stroke Depression
Condition: Post-stroke Depression
MeSH terms: Stroke; Depression; Depressive Disorder
Study type: Interventional

Summary: 
      The purpose of this study is to find alternative treatments for patient's suffering from
      depression after having a stroke.This study aims to show that accelerated rTMS is a safe,
      effective,and convenient treatment for patient's suffering from post-stroke depression in the
      acute to subacute phase. This will be an open label trial and thus all participants will
      receive the active rTMS intervention.
    

Detailed description: 
      The primary objectives of this project are as follows:

        1. To assess the efficacy TMS in PSD. We hypothesize that there will be a decrease in the
           HAMD score in patients receiving TMS

        2. To assess the feasibility of an accelerated protocol using rTMS in patients with acute
           to subacute stroke and co-existing PSD. We hypothesize that the accelerated protocol
           will promote compliance in our patient population and that the administration of this
           intervention is feasible.

        3. To assess the safety of rTMS in patients with acute to subacute stroke. We hypothesize
           that the side effects of TMS will be minimal and the therapy will be well-tolerated and
           safe in individuals with recent strokes and co-existing PSD.
    

Intervention name(s): TMS
Intervention type(s): Device
Intervention description(s): NeuroStar TMS Therapy
Intervention model: Single Group Assignment
Intervention model description: Open label
Masking: None (Open Label)
Primary purpose: Treatment
Calculating Blood Volume by Dilution of Hemoglobin - Pilot Study
Condition: Determine Validity of Concept of Using Hemoglobin Dilution to Assess/Measure Blood Volume.
Study type: Interventional

Summary: 
      Although blood volume is such an important parameter in everyday clinical medicine it cannot
      be measured easily. As a matter of fact, it is almost never measured but estimated or
      calculated based upon numbers derived from mostly healthy patients.

      The investigators do not even know whether someone's normal - i.e. before a surgery - blood
      volume is actually anywhere close to the generally accepted estimate or calculation.

      Tests exist in which a substance of known concentration is diluted in a person's blood volume
      and the resulting concentration is then measured, which allows the blood volume to be
      calculated. However, none of these tests can be completed at the bedside since they are not
      fast and require considerable set-up.

      This study turns the above approach upside-down: we will dilute the blood slightly with a
      known small volume of an intravenous fluid commonly used in many clinical settings and
      measure the concentra-tion of hemoglobin - the oxygen carrier contained in red blood cells -
      before and after adding the fluid. That allows for similar calculations without using neither
      specialized substances nor equipment.

      Hemoglobin is routinely measured in laboratories and is often a routine test before and
      during surg-eries and in intensive care units.

      Devices that can measure hemoglobin through the skin without actually drawing any blood are
      avail-able. If found comparable to laboratory determination of hemoglobin they could provide
      for a bedside and almost real-time assessment of blood volume, something that could be
      extremely valuable for de-cision making in critical areas of medicine and promoting goal
      directed therapies.
    


Intervention name(s): Blood Volume Dilution
Intervention type(s): Drug
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Diagnostic